Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Piramal Pharma's share price for the quarter that ended in Mar. 2026 was ₹136.54. Piramal Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,325 Mil. Therefore, Piramal Pharma's market cap for the quarter that ended in Mar. 2026 was ₹180,881 Mil.
Piramal Pharma's quarterly market cap
declined
from Sep. 2025 (₹252,801 Mil) to Dec. 2025 (₹227,897 Mil) and
declined
from Dec. 2025 (₹227,897 Mil) to Mar. 2026 (₹180,881 Mil).
Piramal Pharma's annual market cap
increased
from Mar. 2024 (₹169,892 Mil) to Mar. 2025 (₹296,938 Mil) but then
declined
from Mar. 2025 (₹296,938 Mil) to Mar. 2026 (₹180,881 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Piramal Pharma's Enterprise Value for Today is ₹276,789 Mil.
Piramal Pharma (NSE:PPLPHARMA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Piramal Pharma Market Cap Related Terms
Piramal Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Piramal Pharma's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a Market Cap of ₹233,392 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Piramal Pharma and its competitors. According to the industry distribution chart, Piramal Pharma ranks #138 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 13.5%.
Is Piramal Pharma's Market Cap too high?
Piramal Pharma's current Market Cap is ₹233,392 Mil. Based on the distribution chart, Piramal Pharma ranks #138 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Piramal Pharma has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #138 out of 1024 companies for Market Cap. This places Piramal Pharma in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 214.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.89, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current Market Cap is ₹233,392 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹176.30, compared to a current price of ₹175.95 — trading 0.2% below its estimated fair value. The current Market Cap is ₹233,392 Mil. Piramal Pharma's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Market Cap is ₹233,392 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued.
The current stock price of ₹175.95 is trading 0.2% below its estimated GF Value™ of ₹176.30.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
Market Cap: ₹233,392 Mil
GF Value™: ₹176.30 vs. price of ₹175.95 (0.2% below fair value)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
60GF Score
Get the complete analysis for NSE:PPLPHARMA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
